GlassScriptPhysician profile
Mark C Mouton
NPI 1164613758
$8,431.30
in general payments reported to CMS, 2019-2025
54 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $1,187 · 2021: $1,371 · 2022: $1,011 · 2023: $1,314 · 2024: $1,351 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $926.87 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $923.84 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $914.72 | 2021-2025 | |
| Novo Nordisk INC | $625.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $391.79 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $361.80 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $284.97 | 2022-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $284.71 | 2019-2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $271.56 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $268.66 | 2019-2025 | Austedo Xr |
| Avanir Pharmaceuticals, INC. | $256.25 | 2019-2022 | |
| Lundbeck LLC | $244.84 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $230.46 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $207.31 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $168.11 | 2020-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mouton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.